DFFN - Diffusion Pharmaceuticals Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.4239
-0.0161 (-1.1181%)
As of 11:19AM EST. Market open.
Stock chart is not supported by your current browser
Previous Close1.4400
Open1.4300
Bid1.4200 x 4600
Ask1.4400 x 100
Day's Range1.4216 - 1.4385
52 Week Range1.2700 - 15.5000
Volume10,055
Avg. Volume400,032
Market Cap20.677M
Beta-1.12
PE Ratio (TTM)N/A
EPS (TTM)-2.2450
Earnings DateNov 13, 2017 - Nov 17, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est89.30
Trade prices are not sourced from all markets
  • What You Must Know About Diffusion Pharmaceuticals Inc’s (DFFN) Risks
    Simply Wall St.4 days ago

    What You Must Know About Diffusion Pharmaceuticals Inc’s (DFFN) Risks

    If you are looking to invest in Diffusion Pharmaceuticals Inc’s (NASDAQ:DFFN), or currently own the stock, then you need to understand its beta in order to understand how it canRead More...

  • GlobeNewswire22 days ago

    Diffusion Pharmaceuticals Regains Compliance with Nasdaq Capital Market Minimum Equity Rule

    CHARLOTTESVILLE, Va., Nov. 20, 2017-- Diffusion Pharmaceuticals Inc., is a clinical-stage biotechnology company focused on extending the life expectancy of cancer patients using the novel small molecule ...

  • DFFN: FDA Gives Final Guidance for Phase 3 Protocol for TSC in Inoperable GBM
    Zacks Small Cap Research26 days ago

    DFFN: FDA Gives Final Guidance for Phase 3 Protocol for TSC in Inoperable GBM

    On November 13, 2017, Diffusion Pharmaceuticals, Inc. (DFFN) announced financial results for the third quarter of 2017. As expected, the company did not report any revenues. Diffusion reported net income of $5.1 million, or $0.37 per share, which was the result of a non-cash gain of $8.4 million related to the change in the fair value of warrant liabilities due to a decrease in the fair market value of the company’s common stock and not indicative of ongoing operations.

  • GlobeNewswire29 days ago

    Diffusion Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Business Update

    FDA Clears Phase 3 Protocol for Patient Enrollment in GBM Brain Cancer Trial“ First Patient In” Expected this Year Company Charter Amendment Addresses Nasdaq Listing Issue Additions to Board and Management ...

  • ACCESSWIRE2 months ago

    Today's Research Reports on Stocks to Watch: Neothetics, Inc. and Diffusion Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / October 18, 2017 / Shares of Neothetics and Diffusion Pharmaceuticals saw big gains in Tuesday trading after the companies had positive news respectively. Neothetics soared ...

  • Diffusion Pharmaceuticals Inc to Initiate Phase 3 Trial in Inoperable GBM; Shares Soar 35%
    SmarterAnalyst2 months ago

    Diffusion Pharmaceuticals Inc to Initiate Phase 3 Trial in Inoperable GBM; Shares Soar 35%

    Diffusion Pharmaceuticals Inc (NASDAQ:DFFN) is a mover and shaker out on the Street today, with investors sparking the stock on an almost 35% upturn. The US drug discovery and development firm announced that it has received final protocol guidance from the FDA for a Phase 3 clinical trial with the Company’s lead compound trans sodium crocetinate (TSC) in patients newly diagnosed with inoperable glioblastoma multiforme (GBM), a type of brain cancer. The Company has responded to all outstanding points raised by the FDA and plans to begin the trial under the protocol agreed to by the FDA by the end of 2017.

  • GlobeNewswire2 months ago

    Diffusion Pharmaceuticals to Present at the 2017 BIO Investor Forum

    CHARLOTTESVILLE, Va., Oct. 10, 2017-- Diffusion Pharmaceuticals Inc., a clinical-stage biotechnology company focused on the development of novel small molecule therapeutics for cancer and other hypoxia-related ...

  • Is It The Right Time To Buy Diffusion Pharmaceuticals Inc (DFFN)?
    Simply Wall St.3 months ago

    Is It The Right Time To Buy Diffusion Pharmaceuticals Inc (DFFN)?

    Diffusion Pharmaceuticals Inc (NASDAQ:DFFN), a pharmaceuticals, biotechnology and life sciences company based in United States, Check out our latest analysis for Diffusion Pharmaceuticals Is DFFN still cheap? Great news forRead More...

  • Zacks Small Cap Research3 months ago

    DFFN: Phase 3 Trial of TSC in GBM to Initiate Before End of 2017

    Diffusion (DFFN) is a biopharmaceutical company focused on the development of treatments that augment the effects seen from current standard of care cancer therapies. The company’s lead compound is trans sodium crocetinate (TSC), a small molecule that improves the diffusion of oxygen through the bloodstream in order to increase tissue oxygenation. This increase in oxygenation results in increased efficacy for radiation and chemotherapeutic cancer treatments, particularly for those that target hypoxic tumors such as glioblastoma multiforme (GBM) and pancreatic cancer.

  • Accesswire5 months ago

    Today's Research Reports on Trending Tickers: Diffusion Pharmaceuticals Inc. and Juno Therapeutics Inc.

    NEW YORK, NY / ACCESSWIRE / July 21, 2017 / U.S. markets were mixed Thursday as a sharp drop in Home Depot shares dragged down the Dow Jones and S&P 500 Index, while the Nasdaq continued to climb to new ...

  • Accesswire7 months ago

    Diffusion Pharmaceuticals to Present at the 7th Annual LD Micro Invitational

    LOS ANGELES, CA / ACCESSWIRE / May 26, 2017 / Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN), a clinical stage biotechnology company focused on improving the results of cancer treatments such as radiation ...

  • Zacks Small Cap Research7 months ago

    DFFN: Focusing on Inoperable GBM Patients for Phase 3 Trial of TSC…

    On May 15, 2017, Diffusion Pharmaceuticals, Inc. (DFFN) announced financial results for the first quarter of 2017. As expected, the company did not report any revenues. The decrease was due to decreased expenses attributable to the pancreatic cancer program and animal toxicology.

  • Zacks Small Cap Research8 months ago

    DFFN: Phase 3 Trial of TSC in GBM to Initiate in 2017

    On March 31, 2017, Diffusion (DFFN) announced financial results for the fourth quarter and full year for 2016. For the full year, Diffusion had a net loss of $18.0 million, or $1.76 per share, which was comprised of $7.3 million in R&D expenses and $11.0 million in G&A expenses compared to $3.9 million in R&D expenses and $2.5 million in G&A expenses for 2015. In April 2017, Diffusion announced the closing of an oversubscribed private placement that raised gross proceeds of $25.0 million from the sale of approximately 12.4 million shares of Series A Convertible Preferred Stock for $2.02 per share.

  • Accesswire8 months ago

    Diffusion Pharmaceuticals Gets Professional Recognition and Akers Biosciences Achieves a First

    NEW YORK, NY / ACCESSWIRE / March 29, 2017 / These two companies, one involved in cancer drug research, the other in cholesterol testing devices, both saw their stocks rise as investors heard of their ...

  • 24/7 Wall St.10 months ago

    Wednesday’s Biggest Biopharma Movers

    Not that many biotech and pharma companies were on the move Wednesday, but a few of the smaller caps made splash, while one giant company posted a massive loss.